Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: In the NETTER-1 study, peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE increased progression-free survival (PFS) and time to deterioration in quality of life (QoL) in patients with advanced midgut neuroendocrine tumours (NETs), compared with octreotide.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Keywords: 177Lu-DOTATATE, metastases, quality of life,
Introduction: Malignant hypercalcemia due to neuroendocrine tumor(NET) is rare, and only a few reports are available in the literature.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Wang C
Authors: Wang C, Qi Z, Tan H, Tan H,
Keywords: hypercalcemia, pancreatic NET, sunitinib,
Introduction: The incidence of BM in NET is underestimated and there is no consensus on clinical features, diagnostic techniques, and treatment options.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Smiroldo V
Authors: Smiroldo V, Lania A, Pedicini V, Pepe G, Zerbi A,
Keywords: bone metastases, skeletal related event, survival, bisphosphonates, 68Ga-PET, 18FDG-PET, CT scan,
Introduction: The incidence of bone metastases (BM) in patients with NENs is 12-25%, and skeletal related events (SREs) occur in up to 21% of affected cases. Data about the efficacy of bisphosphonates in NEN patients (pts) with BM are limited.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Armeni E, Hayes A, Gopaul A, Aristidou I, Navalkissoor S,
Keywords: bone metastases, NEN, zoledronic acid, skeletal related event,
Introduction: Somatostatin analogues (SSA), octreotide LAR (Oct) and lanreotide autogel (Lan), significantly prolong progression-free survival (PFS) in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET). However, comparative data are not available and randomized trials comparing both SSAs are unlikely to be conducted.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Carmona-Bayonas A, Jimenez-Fonseca P, Lamarca A, Barriuso J, Castaño A,
Keywords: Bayesian model, octreotide, lanreotide, progression-free survival, efficacy,